首页> 外文期刊>Experimental and therapeutic medicine >Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease
【24h】

Levels of acylation stimulating protein and the complement component 3 precursor are associated with the occurrence and development of coronary heart disease

机译:酰化刺激蛋白和补体成分3前体的水平与冠心病的发生和发展有关

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study was to investigate whether acylation stimulating protein (ASP) and complement component 3 (C3) are associated with the occurrence and development of coronary heart disease (CHD). The participants of the study were divided into three groups, including the healthy control (n=42), metabolic syndrome (MS, n=56) and CHD (n=62) groups. An enzyme-linked immunosorbent assay was used to measure the ASP concentrations, while an immunoturbidimetric assay was employed to determine the C3 concentrations. In addition, coronary angiography was performed to determine the severity of coronary artery disease in the CHD group. The CHD group was divided into three subgroups, according to the final Gensini score of coronary artery stenosis for each patient (mild, <= 20 points; moderate, 21-40 points; severe, >40 points). Western blotting and quantitative reverse transcription-polymerase chain reaction (RT-PCR) were performed to analyze the protein and mRNA expression levels of C3 in the CHD subgroups and the healthy control group. The concentrations of ASP and C3 in the CHD group were found to be significantly higher compared with the control and MS groups. In addition, the levels of ASP and C3 in the mild and moderate CHD subgroups were significantly higher compared with the healthy controls or mild CHD patients. Furthermore, the protein expression levels of C3 in the moderate and severe CHD patients were found to be significantly higher compared with the healthy individuals and the mild CHD patients. The quantitative RT-PCR results revealed that the m RNA expression levels of C3 in the moderate and severe CHD patients were significantly higher compared with the healthy control group and the mild CHD patients. Furthermore, the mean levels of C3 transcripts in the severe CHD patients were found to be higher compared with the moderate CHD subgroup (P<0.05). Therefore, ASP and C3 were found to be associated with the occurrence and development of CHD; thus, may be used as novel indexes for CHD.
机译:本研究的目的是研究酰化刺激蛋白(ASP)和补体成分3(C3)是否与冠心病(CHD)的发生和发展有关。研究的参与者分为三组,包括健康对照组(n = 42),代谢综合征(MS,n = 56)和冠心病(n = 62)组。酶联免疫吸附测定法用于测定ASP浓度,而免疫比浊测定法用于测定C3浓度。另外,进行冠状动脉造影以确定冠心病组中冠状动脉疾病的严重程度。根据每位患者的冠状动脉狭窄最终Gensini评分,CHD组分为三个亚组(轻度,<= 20分;中度,21-40分;重度,> 40分)。进行了蛋白质印迹和定量逆转录聚合酶链反应(RT-PCR),以分析冠心病亚组和健康对照组中C3的蛋白质和mRNA表达水平。与对照组和MS组相比,CHD组的ASP和C3浓度明显更高。此外,与健康对照组或轻度冠心病患者相比,轻度和中度冠心病亚组的ASP和C3水平显着更高。此外,发现中度和重度冠心病患者的C3蛋白表达水平显着高于健康个体和轻度冠心病患者。定量RT-PCR结果显示,中,重度冠心病患者的C3 mRNA表达水平明显高于健康对照组和轻度冠心病患者。此外,发现重度冠心病患者的平均C3转录水平高于中度冠心病亚组(P <0.05)。因此,发现ASP和C3与CHD的发生和发展有关。因此,可用作冠心病的新指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号